Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
ESMO 2021: Recommendations From Dr. David Henry
- Written by
-
David
Henry
MD
Friday, September 17, 2021
Channel 2
1:30 PM–2:50 PM CEST; Proffered Paper Session
Non-Metastatic NSCLC and Other Thoracic Malignancies
LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743. S Peters
Saturday, September 18, 2021
Channel 1
3:05 PM–4:35 PM CEST; Presidential Symposium 1
LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. J Cortés
Sunday, September 19, 2021
Channel 1
3:05 PM–4:37 PM CEST; Presidential Symposium 2
LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. J Weiss
Sunday, September 19, 2021
Channel 3
5:30 PM–6:20 PM CEST; Mini Oral Session
Haematological Malignancies
829MO A gene signature to predict risk of transformation in patients with follicular lymphoma. I Fernandez-Miranda
Monday, September 20, 2021
Channel 1
3:05 PM–4:35 PM CEST; Presidential Symposium 3
LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors. S Oosting
LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. E Felip
On-Demand ePosters
Biomarkers (Agnostic)
69P Transferrin saturation shows high prevalence of iron deficiency in cancer patients under adjuvant and neo-adjuvant treatment. E Luporsi-Gely
Breast Cancer, Early Stage
152P Meta-analysis of the prognostic value of circulating tumor DNA (ctDNA) in patients (pts) with early breast cancer (EBC). NS Gonzalez
Pancreatic Cancer
1472P Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study. C Evrard
Colorectal Cancer
458P Circulating tumor DNA analysis predicting recurrence risk in patients with stage I-III colorectal cancer. J Gu